Management of Glucocorticoid-Induced Hyperglycemia

References

• Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Miñambres I, Gomez-Huelgas R. Glucocorticoid-induced hyperglycemia. J Diabetes. 2014;6(1):9–20. doi:10.1111/1753-0407.12090
   PubMed Web of Science ®Google Scholar
• Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med. 2002;17(9):717–720. doi:10.1046/j.1525-1497.2002.10649.x
   PubMed Web of Science ®Google Scholar
• Liu X, Zhu X, Miao Q, Ye H, Zhang Z. Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis. Ann Nutr Metab. 2014;65(4):324–332. doi:10.1159/000365892
   PubMed Web of Science ®Google Scholar
• Kwon S, Hermayer KL, Hermayer K. Glucocorticoid-induced hyperglycemia. Am J Med Sci. 2013;345(4):274–277. doi:10.1097/MAJ.0b013e31828a6a01
   Web of Science ®Google Scholar
• Suh S, Park MK. Glucocorticoid-induced diabetes mellitus: an important but overlooked problem. Endocrinol Metab. 2017;32(2):180–189. doi:10.3803/EnM.2017.32.2.180
   Web of Science ®Google Scholar
• Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract. 2009;15(5):469–474. doi:10.4158/EP08331.RAR
   PubMed Web of Science ®Google Scholar
• 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2021 | diabetes care. Available from: https://care.diabetesjournals.org/content/44/Supplement_1/S15. Accessed May 31, 2021.
   Google Scholar
• Farrokhi F, Smiley D, Umpierrez GE. Glycemic control in non-diabetic critically ill patients. Best Pract Res Clin Endocrinol Metab. 2011;25(5):813–824. doi:10.1016/j.beem.2011.05.004
   Web of Science ®Google Scholar
• Kamceva G, Vavlukis M, Kitanoski D, Kedev S. Newly diagnosed diabetes and stress glycaemia and its’ association with acute coronary syndrome. Open Access Maced J Med Sci. 2015;3(4):607–612. doi:10.3889/oamjms.2015.103
   Google Scholar
• Roberts A, James J, Dhatariya K; Joint British Diabetes Societies (JBDS) for Inpatient Care. Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabet Med. 2018;35(8):1011–1017. doi:10.1111/dme.13675
   Web of Science ®Google Scholar
• Castilla-Guerra L, Fernández-Moreno MC, Hewitt J. Treatment of hyperglycemia in patients with acute stroke. Revista Clínica Española. 2016;216(2):92–98. doi:10.1016/j.rceng.2015.08.002
   Web of Science ®Google Scholar
• Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30. doi:10.1186/1710-1492-9-30
   PubMed Web of Science ®Google Scholar
• Clinical pharmacokinetics of prednisone and prednisolone - PubMed. Available from: https://pubmed.ncbi.nlm.nih.gov/378499/. Accessed December 27, 2021.
   Google Scholar
• Möllmann H, Hochhaus G, Rohatagi S, Barth J, Derendorf H. Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Pharm Res. 1995;12(7):1096–1100. doi:10.1023/a:1016287104656
   PubMed Web of Science ®Google Scholar
• Derendorf H, Möllmann H, Barth J, Möllmann C, Tunn S, Krieg M. Pharmacokinetics and oral bioavailability of hydrocortisone. J Clin Pharmacol. 1991;31(5):473–476. doi:10.1002/j.1552-4604.1991.tb01906.x
   PubMed Web of Science ®Google Scholar
• Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med. 2009;103(7):975–994. doi:10.1016/j.rmed.2009.01.003
   PubMed Web of Science ®Google Scholar
• Buttgereit F, da Silva J a P, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61(8):718–722. doi:10.1136/ard.61.8.718
   PubMed Web of Science ®Google Scholar
• JBDS management of hyperglycaemia and steriod therapy_0.pdf. Available from: https://www.diabetes.org.uk/resources-s3/2017-09/JBDS%20management%20of%20hyperglycaemia%20and%20steriod%20therapy_0.pdf. Accessed May 31, 2021.
   Google Scholar
• Gosmanov AR, Umpierrez GE. Management of hyperglycemia during enteral and parenteral nutrition therapy. Curr Diab Rep. 2013;13(1):155–162. doi:10.1007/s11892-012-0335-y
   PubMed Web of Science ®Google Scholar
• Pleva M, Mirtallo JM, Steinberg SM. Hyperglycemic events in non-intensive care unit patients receiving parenteral nutrition. Nutr Clin Pract. 2009;24(5):626–634. doi:10.1177/0884533609339069
   PubMed Web of Science ®Google Scholar
• Rosmarin DK, Wardlaw GM, Mirtallo J. Hyperglycemia associated with high, continuous infusion rates of total parenteral nutrition dextrose. Nutr Clin Pract. 1996;11(4):151–156. doi:10.1177/0115426596011004151
   PubMedGoogle Scholar
• Arinzon Z, Shabat S, Shuval I, Peisakh A, Berner Y. Prevalence of diabetes mellitus in elderly patients received enteral nutrition long-term care service. Arch Gerontol Geriatr. 2008;47(3):383–393. doi:10.1016/j.archger.2007.09.001
   Web of Science ®Google Scholar
• Pancorbo-Hidalgo PL, García-Fernandez FP, Ramírez-Pérez C. Complications associated with enteral nutrition by nasogastric tube in an internal medicine unit. J Clin Nurs. 2001;10(4):482–490. doi:10.1046/j.1365-2702.2001.00498.x
   PubMed Web of Science ®Google Scholar
• Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on inpatient glycemic control. Diabetes Care. 2009;32(6):1119–1131. doi:10.2337/dc09-9029
   PubMed Web of Science ®Google Scholar
• Rice MJ, Smith JL, Coursin DB. Glucose measurement in the ICU: regulatory intersects reality. Crit Care Med. 2017;45(4):741–743. doi:10.1097/CCM.0000000000002274
   Web of Science ®Google Scholar
• Rodbard HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(Suppl 1):1–68. doi:10.4158/EP.13.S1.1
   PubMedGoogle Scholar
• Vaaler S. Optimal glycemic control in type 2 diabetic patients. Does including insulin treatment mean a better outcome? Diabetes Care. 2000;23(Suppl 2):B30–34.
   Google Scholar
• Lakhani OJ, Kumar S, Tripathi S, Desai M, Seth C. Comparison of two protocols in the management of glucocorticoid-induced hyperglycemia among hospitalized patients. Indian J Endocrinol Metab. 2017;21(6):836–844. doi:10.4103/ijem.IJEM_226_17
   PubMedGoogle Scholar
• Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40(12):1631–1640. doi:10.2337/dc17-1600
   PubMed Web of Science ®Google Scholar
• Dashora UK, Taylor R. Maintaining glycaemic control during high-dose prednisolone administration for hyperemesis gravidarum in Type 1 diabetes. Diabet Med. 2004;21(3):298–299. doi:10.1046/j.1464-5491.2003.01026_21_3.x-i1
   Web of Science ®Google Scholar
• DARE-19: dapagliflozin in high-risk patients hospitalized with COVID-19. American College of Cardiology. Available from: https://www.acc.org/latest-in-cardiology/articles/2021/05/12/19/08/http%3a%2f%2fwww.acc.org%2flatest-in-cardiology%2farticles%2f2021%2f05%2f12%2f19%2f08%2fsun-8am-dare-19-acc-2021. Accessed July 9, 2021.
   Google Scholar
• Bellido V, Suarez L, Rodriguez MG, et al. Comparison of basal-bolus and premixed insulin regimens in hospitalized patients with type 2 diabetes. Diabetes Care. 2015;38(12):2211–2216. doi:10.2337/dc15-0160
   PubMed Web of Science ®Google Scholar
• Ilag LL, Kerr L, Malone JK, Tan MH. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Ther. 2007;29(6 Pt 1):1254–1270. doi:10.1016/j.clinthera.2007.07.003
   Web of Science ®Google Scholar
• Garber AJ, Ligthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab. 2007;9(5):630–639. doi:10.1111/j.1463-1326.2006.00654.x
   PubMed Web of Science ®Google Scholar
• Use of variable rate intravenous insulin infusion in medical inpatients_0.pdf. Available from: https://www.diabetes.org.uk/resources-s3/2017-09/Use%20of%20variable%20rate%20intravenous%20insulin%20infusion%20in%20medical%20inpatients_0.pdf. Accessed May 31, 2021.
   Google Scholar
• Yata Y, Hosojima M, Kabasawa H, et al. The assessment of the efficacy of dipeptidyl peptidase-4 inhibitors in patients with glucocorticoid-induced diabetes by continuous glucose monitoring. Intern Med. 2017;56(19):2555–2562. doi:10.2169/internalmedicine.8296-16
   PubMed Web of Science ®Google Scholar
• ICMR_GuidelinesType2diabetes2018_0.pdf. Available from: https://main.icmr.nic.in/sites/default/files/guidelines/ICMR_GuidelinesType2diabetes2018_0.pdf. Accessed June 2, 2021.
   Google Scholar
• Kalra S, Kalra B, Gupta Y. Glycemic management after antenatal corticosteroid therapy. N Am J Med Sci. 2014;6(2):71–76. doi:10.4103/1947-2714.127744
   Google Scholar
• Korytkowski MT, Salata RJ, Koerbel GL, et al. Insulin therapy and glycemic control in hospitalized patients with diabetes during enteral nutrition therapy: a randomized controlled clinical trial. Diabetes Care. 2009;32(4):594–596. doi:10.2337/dc08-1436
   PubMed Web of Science ®Google Scholar
• Diabetes in remission - Hillson - 2017 - practical diabetes - Wiley online library. Available from: 10.1002/pdi.2087. Accessed May 31, 2021.
   Google Scholar
• Nafakhi H, Alareedh M, Al-Buthabhak K, Shaghee F, Nafakhi A, Kasim S. Predictors of adverse in-hospital outcome and recovery in patients with diabetes mellitus and COVID-19 pneumonia in Iraq. Diabetes Metab Syndr. 2021;15(1):33–38. doi:10.1016/j.dsx.2020.12.014
   Web of Science ®Google Scholar
• Gupta Y, Goyal A, Kubihal S, Golla KK, Tandon N. A guidance on diagnosis and management of hyperglycemia at COVID care facilities in India. Diabetes Metab Syndr. 2021;15(1):407–413. doi:10.1016/j.dsx.2021.01.015
   Web of Science ®Google Scholar
• Yanai H, Masui Y, Yoshikawa R, Kunimatsu J, Kaneko H. Dipeptidyl peptidase-4 inhibitor for steroid-induced diabetes. World J Diabetes. 2010;1(3):99–100. doi:10.4239/wjd.v1.i3.99
   Google Scholar
• Filozof C, Schwartz S, Foley JE. Effect of vildagliptin as add-on therapy to a low-dose metformin. World J Diabetes. 2010;1(1):19–26. doi:10.4239/wjd.v1.i1.19
   PubMedGoogle Scholar
• López-Carmona MD, Gómez-Huelgas R, Corpas E. Chapter 17 - diabetes mellitus in the elderly. In: Corpas E, editor. Endocrinology of Aging. Elsevier; 2021:547–576. doi:10.1016/B978-0-12-819667-0.00017-2
   Google Scholar
• Loew D, Schuster O, Graul EH. Dose-dependent pharmacokinetics of dexamethasone. Eur J Clin Pharmacol. 1986;30(2):225–320. doi: 10.1007/BF00614309
   Google Scholar
• Clinical Guidance on Diabetes Management at COVID-19 Patient Management Facility; Version 1.0. AIIMS; 2020. Available from: https://covid.aiims.edu/wp-content/uploads/2020/07/Diabetes-management-at-COVID-facility..pdf. Accessed April 19, 2020.
   Google Scholar